Needle-free COVID vaccine trials begin with help of ‘special’ participants and dogs

Research is underway on a new, needle-free vaccine that scientists believe has the potential to be better than injected vaccines. Cincinnati Children’s Hospital is participating in the trial. “This is an experimental COVID vaccine trial by intranasal administration.” Children’s Hospital Dr. Paul Spearman. For many, the lack of needles is enough to give it an advantage over all other COVID-19 vaccines, but researchers say there are other reasons. The site where the virus may attack. It can prevent primary infection. That could also prevent the spread of the virus, Spearman said. The study will look at adults who have not had COVID-19 and have not been vaccinated for it, and Spearman said, “It’s a challenge.” “It’s a special group of people that we’re really looking for.” The researchers just opened the door for registration. So far, 11 adults have registered, but they hope to get about 80, and the new vaccine uses live virus like other flu vaccines. This one has a vector that hasn’t been used in humans before, but scientists believe it’s safe because people have come into contact with it through their pets. “The Pi5 virus itself, parainfluenza virus type 5, is part of the kennel cough vaccine that is given to dogs, and people are exposed to that. We know they do because that has been evaluated and as far as we know, they have never developed symptoms,” Spearman said. Participants get an incentive of $975.00, but even though it’s a needle-free vaccine, those who participate in the study will have to have blood drawn with a needle. To register, click here redcap.link/COVID-19Vaccine

Research is underway on a new, needle-free vaccine that scientists believe has the potential to be better than injected vaccines.

Cincinnati Children’s Hospital enrolls in the trial.

“This is an experimental COVID vaccine trial by intranasal administration,” said Dr. Paul Spearman at Children’s Hospital.

For many, the lack of needles is enough to give it an advantage over all other COVID-19 vaccines, but researchers say there are other reasons.

“It has the potential advantage of mucosal immunogenicity, which means that it is located directly at the site where the virus might attack. It can prevent primary infection. That may prevent the spread of the virus,” Spearman said.

Children is one of three sites across the country studying the nasal COVID-19 vaccine.

An experiment looks for a specific type of participant. The study will look at adults who have not had COVID-19 and have not had a vaccine.

“It’s a challenge,” Spearman said. “It’s a special group of people that we’re really looking for.”

The researchers just opened the registry. So far, they have 11 adults registered, but they hope to have about 80.

The new vaccine uses live virus like other flu vaccines.

This vector has a vector that has not been used in humans before, but scientists believe it is safe because people have come into contact with it through their pets.

The Pi5 virus itself, parainfluenza virus type 5, is part of the cough vaccine given to dogs, and people are exposed to it. We know they’re doing it because it’s been evaluated and as far as we know, they’ve never had symptoms,” Spearman said.

Participants get an incentive of $975.00, but even though it’s a needle-free vaccine, those who participate in the study will have to draw blood with a needle.

To register, click here redcap.link/COVID-19Vaccin

.

Add a Comment

Your email address will not be published. Required fields are marked *